AbbVie Total Non-Operating Income/Expense 2012-2026 | ABBV

AbbVie annual/quarterly total non-operating income/expense history and growth rate from 2012 to 2026. Total non-operating income/expense can be defined as the sum of all non-operating expenses for the given industry.
  • AbbVie total non-operating income/expense for the quarter ending March 31, 2026 was $-2.951B, a 42.42% increase year-over-year.
  • AbbVie total non-operating income/expense for the twelve months ending March 31, 2026 was $-9.357B, a 45.07% increase year-over-year.
  • AbbVie annual total non-operating income/expense for 2025 was $-8.362B, a 54.25% increase from 2024.
  • AbbVie annual total non-operating income/expense for 2024 was $-5.421B, a 16.69% decline from 2023.
  • AbbVie annual total non-operating income/expense for 2023 was $-6.507B, a 40.24% increase from 2022.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
AbbVie Annual Total Non-Operating Income/Expense
(Millions of US $)
2025 $-8,362
2024 $-5,421
2023 $-6,507
2022 $-4,640
2021 $-4,935
2020 $-7,965
2019 $-4,557
2018 $-1,186
2017 $-1,818
2016 $-1,456
2015 $-892
2014 $-1,042
2013 $-332
2012 $-92
2011 $48
AbbVie Quarterly Total Non-Operating Income/Expense
(Millions of US $)
2026-03-31 $-2,951
2025-12-31 $-1,876
2025-09-30 $-1,190
2025-06-30 $-3,340
2025-03-31 $-2,072
2024-12-31 $-779
2024-09-30 $-1,747
2024-06-30 $-1,852
2024-03-31 $-1,043
2023-12-31 $-1,983
2023-09-30 $-328
2023-06-30 $-1,903
2023-03-31 $-2,293
2022-12-31 $-2,537
2022-09-30 $-203
2022-06-30 $-2,112
2022-03-31 $212
2021-12-31 $-803
2021-09-30 $-618
2021-06-30 $-3,278
2021-03-31 $-236
2020-12-31 $-5,260
2020-09-30 $-755
2020-06-30 $-1,445
2020-03-31 $-505
2019-12-31 $-882
2019-09-30 $-616
2019-06-30 $-2,593
2019-03-31 $-466
2018-12-31 $68
2018-09-30 $-398
2018-06-30 $-750
2018-03-31 $-106
2017-12-31 $-589
2017-09-30 $-599
2017-06-30 $-309
2017-03-31 $-321
2016-12-31 $-316
2016-09-30 $-347
2016-06-30 $-291
2016-03-31 $-502
2015-12-31 $-189
2015-09-30 $-238
2015-06-30 $-174
2015-03-31 $-291
2014-12-31 $-622
2014-09-30 $-273
2014-06-30 $-82
2014-03-31 $-65
2013-12-31 $-96
2013-09-30 $-85
2013-06-30 $-85
2013-03-31 $-66
2012-12-31 $-108
2012-09-30 $8
2012-06-30 $-20
2012-03-31 $28
2011-12-31 $14
2011-09-30
2011-06-30
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $367.673B $61.160B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $887.629B 38.81
Johnson & Johnson (JNJ) United States $574.358B 22.08
Roche Holding AG (RHHBY) Switzerland $318.782B 0.00
Merck (MRK) United States $299.893B 13.54
Novartis AG (NVS) Switzerland $293.951B 17.16
Novo Nordisk (NVO) Denmark $167.527B 9.60
Pfizer (PFE) United States $153.074B 8.33
Sanofi (SNY) France $114.048B 10.56
Bayer (BAYRY) Germany $46.178B 8.70
Innoviva (INVA) United States $1.760B 5.88